UNSPSC 51372100: Controlled substance analgesic morphine derivatives

Controlled substance analgesic drugs made from the principal alkaloid in opium and the prototype opiate analgesic and narcotic.

UNSPSC 51372100 Controlled substance analgesic morphine derivatives is a Class code encompassing the procurement of prescription and over-the-counter pharmaceutical products by state and local health agencies, including county health departments, state HHS commissions, and cooperative purchasing alliances. State and local buyers acquire generic and branded pharmaceuticals, naloxone and emergency medical supplies, and controlled-substance analgesics through competitive bidding and cooperative purchasing vehicles. The issuing bodies are predominantly state health and human services departments, county community health offices, and multi-state cooperative purchasing organizations such as MMCAP that aggregate demand across member jurisdictions.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program that would enable direct contracting between state pharmacy benefit programs and pharmaceutical manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and over-the-counter products to be supplied through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson), with proposals due March 26, 2026, and awarded vendors effective July 1, 2026; evaluation weighted price competitiveness at 75 percent and required vendors to maintain commercial general liability coverage of $5,000,000 per occurrence and comply with current Good Manufacturing Practices and the Drug Supply Chain Security Act.